Antiarrhythmic drugs and devices for the management of ventricular tachyarrhythmia in ischemic heart disease

American Journal of Cardiology

Volumn 82, Issue 4 A, 1998, Pages 31I-40I

  Reiffel, James A ^a   Reiter, Michael J ^b   Blitzer, Mark ^b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENCAINIDE; FLECAINIDE; IMIPRAMINE; METOPROLOL; MEXILETINE; MORACIZINE; PIRMENOL; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVERSION; CLINICAL TRIAL; CONFERENCE PAPER; DEFIBRILLATOR; DEVICE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT DISEASE; SUDDEN DEATH; SURVIVAL; SYMPTOMATOLOGY;

EID: 0032552042     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00470-6     Document Type: Conference Paper

References (53)

1. Marchlinski FE. Ventricular tachycardia: clinical presentation, course, and treatment. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: WB Saunders, 1990:756-777.
2. Graham SM. A review of long-term beta-blocker trials in survivors of myocardial infarction. (Abstr.) Circulation 1983;67(suppl I):I-46.
3. Yusef S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
4. Pratt E, Lichstein E. Ventricular antiarrhythmic effects of beta adrenergic blocker drugs: a review of mechanism and clinical studies. J Clin Pharmacol 1982;22:335-347.
5. Reiter MJ, Reiffel JA. The importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 1998;82:9I-19I.
6. The CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. (Special report.) N Engl J Med 1989;321:406-412.
7. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
8. Impact Research Group. International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984;4:1148-1163.
9. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993;270:1589-1595.
10. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
11. The DIAMOND Study Group, Denmark. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol 1997;20:704-710.
12. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;i:1142-1147.
13. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, Dyduszynski A, Maciejewicz J, Zaleska T, Lazarczyk-Kedzia E, Motyka J, Paczkowska B, Sczaniecka O, Yusuf S. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-1062.
14. Cairns JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial pilot study. Circulation 1991; 84:550-557.
15. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-1718.
16. Pfisterer M, Kiowski W, Burkhardt D, Follath F, Burkart F. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmia after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 1992;69:1399-1402.
17. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674.
18. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-682.
19. Wilber DJ, Olshansky B, Moran JF, Scanlon PJ. Electrophysiological testing and nonsustained ventricular tachycardia: use and limitations in patients with coronary artery disease and impaaied ventricular function. Circulation 1990;82: 350-358.
20. Bigger JT, Coromilas J, Weld FM, Reiffel JA, Rolnitzky L. Prognosis after recovery from acute myocardial infarction. Ann Rev Med 1984;35:127-147.
21. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M, for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-1940.
22. Buxton AE, Fisher JT, Josephson ME, Lee KL, Pryor DB, Prystowsky EL, Simson MB, DiCarlo L, Echt DS, Packer D, et al. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993;36:215-226.
23. Mason JW, for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993;329:445-451.
24. Steinbeck G, Andresen D, Bach P, Haberl R, Oeff M, Hoffmann E, von Leitner E-R. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med 1992;327:987-992.
25. Bôcker D, Haverkamp W, Block M, Borggrefe M, Hammel D, Breithardt G. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation 1996;94:151-157.
26. Mason JW, for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-458.
27. Reiffel JA, Hahn E, Hartz V, Reiter MJ, for the ESVEM Investigators. Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. Am J Cardiol 1997;79:1048-1053.
28. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280-287.
29. Amiodarone vs Sotalol Study Group. Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Eur Heart J 1989;10:685-694.
30. Mason JW, Marcus FI, Bigger JT, Lazzara R, Reiffel JA, Reiter MJ, Mann D. A summary and assessment of the findings and conclusions of the ESVEM trial. Prog Cardiovasc Dis 1996;38:347-358.
31. Kovoor P, Yung A, Byth N, Eipper VE, Cousins KL, Uther JB, Cooper MJ, Ross DL. Comparison of sotalol, amiodarone and automatic implantable cardioverter defibrillator for treatment of documented spontaneous sustained ventricular tachyarrhythmias secondary to coronary artery disease. (Abstr.) Circulation 1995;92:I-782.
32. Kopp DE, Blakeman BP, Kall JG, Olshansky B, Kinder CA, Wilber DJ. Predictors of defibrillation energy requirements with nonepicardial lead systems. PACE 1995;18:253-260.
33. Jung W, Manz M, Pizzulli L, Pfeiffer D, Lüderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992;70:1023-1027.
34. Bôcker D, Block M, Isbruch F, Wietholt D, Hamme D, Borggrefe M, Breithardt G. Do patients with an implantable defibrillator live longer? J Am Coll Cardiol 1993;21:1638-1644.
35. The PCD Investigator Group. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: an international multicenter study. J Am Coll Cardiol 1994;23:1521-1530.
36. Saksena S, Paczobatt-Johanos M, Castle LW, Forgoros RN, Alpert BL, Kron J. Long term multicenter experience with a second generation implantable pacemaker defibrillator in patients with malignant ventricular tachyarrhythmias. J Am Coll Cardiol 1992;19:490-499.
37. Lehmann MH, Thomas A, Jackson K, Steinman RT, Shah M, Schuger C, Meissner MD, Mosteller R. Long-term outcome with implantable cardioverter defibrillator (ICD) therapy in a multicenter investigator-edited database. (Abstr.) Circulation 1990;82:III-166.
38. Winkle RA, Mead RH, Ruder MA, Gaudiani VA, Smith NA, Buch WS, Schmidt P, Shipman T. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989;13:1353-1361.
39. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994;127:1139-1144.
40. Thomas AC, Moser SA, Smutka ML, Wilson PA. Implantable defibrillation: eight years' clinical experience. PACE 1988;11:2053-2058.
41. Newman D, Sauve MJ, Herre J, Langberg JJ, Lee MA, Titus C, Franklin J, Scheinman MM, Griffin JC. Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992;69:899-903.
42. Powell AC, Fuchs T, Finkelstein DM, Garan H, Cannom DS, McGovern BA, Kelly E, Vlahakes GJ, Torchiana DF, Ruskin JN. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88:1083-1092.
43. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. Exploration of the precision of classifying sudden cardiac death: implications for the interpretation of clinical trials. Circulation 1996;93:519-524.
44. Choue CW, Kim SG, Ferrick KJ, Roth JJ, Fisher JD. Survival rates of patients with malignant ventricular arrhythmia: comparison of medical therapy versus implanted defibrillator therapy. (Abstr.) Circulation 1991;84:II-21.
45. Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D, on behalf of the CIDS co-Investigators. Canadian Implantable Defibrillator Study (CIDS): study design and organization. Am J Cardiol 1993;72(suppl):103F-108F.
46. The Antiarrhythmics Vs Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583.
47. Reiffel JA. Prolonging survival by reducing arrhythmic death: pharmacological therapy of ventricular tachycardia and fibrillation. Am J Cardiol 1997; 80(suppl):45G-55G.
48. Roberts SA, Viana MA, Nazari J, Bauman JL. Invasive and noninvasive methods to predict the long-term efficacy of amiodarone: a compilation of clinical observations using meta-analysis. PACE 1994;17:1590-1602.
49. Schaumann A, von zur Muhlen F, Gonska B-D, Kreuzer H. Enhanced detection criteria in implantable cardioverter-defibrillators to avoid inappropriate therapy. Am J Cardiol 1996;78:42-50.
50. Neuzner J. Safety margins: lessons from the Low Energy Endotak Trial (LEET). Am J Cardiol 1996;78:26-31.
51. Greene HL. Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Am J Cardiol 1996;78:61-66.
52. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R, for the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498.
53. Reiffel JA. Data-driven decisions: the importance of clinical trials in arrhythmia management. J Cardiovasc Pharmacol Ther 1996;1:79-88. AQ1 - AU: designation changed to abstract. Is this correct?